A5005058552- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- RNA Interference and Gene Delivery
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Graphite, nuclear technology, radiation studies
- Antibiotics Pharmacokinetics and Efficacy
- Nuclear and radioactivity studies
- Geological and Geochemical Analysis
- Ferroptosis and cancer prognosis
- Geochemistry and Geologic Mapping
- Protein purification and stability
- Chronic Myeloid Leukemia Treatments
- Radioactive element chemistry and processing
- CNS Lymphoma Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Hydrocarbon exploration and reservoir analysis
- Eosinophilic Disorders and Syndromes
- earthquake and tectonic studies
- COVID-19 Clinical Research Studies
- Acute Lymphoblastic Leukemia research
Baylor College of Medicine
2025
Science for Life Laboratory
2017-2022
Uppsala University
2017-2022
South Valley University
2007
Checkpoint inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC). However, only a minority patients demonstrate durable clinical response. PD-L1 scoring is currently biomarker measure routinely used to select immunotherapy, but its predictive accuracy modest. The aim our study was evaluate proteomic assay analysis patient plasma in context immunotherapy. Pretreatment samples from 43 NSCLC who received anti-PD-(L)1 therapy were analyzed using proximity...
ABSTRACT Lymphomatoid granulomatosis (LYG) is a rare EBV‐driven, extra‐nodal, angiocentric, and angio‐destructive lymphoproliferative disorder. The lungs are the most common site of involvement. We describe case LYG where diagnosis was established based on fine needle aspiration. 58‐year‐old female with history endometrial carcinoma, who presented right upper lobe middle pulmonary nodules which were identified surveillance computed tomography (CT) scan chest. patient underwent an...
Abstract Immune cells of the tumor microenvironment are central but erratic targets for immunotherapy. The aim this study was to characterize novel patterns immune cell infiltration in non‐small lung cancer (NSCLC) relation its molecular and clinicopathologic characteristics. Lymphocytes (CD3+, CD4+, CD8+, CD20+, FOXP3+, CD45RO+), macrophages (CD163+), plasma (CD138+), NK (NKp46+), PD1+, PD‐L1+ were annotated on a tissue microarray including 357 NSCLC cases. Somatic mutations analyzed by...
Cellular immune memory responses post coronavirus disease 2019 (COVID-19) have been difficult to assess due the risks of contaminating response readout with stemming from previous exposure endemic coronaviruses. The work herein presents a large-scale long-term follow-up study investigating correlation between symptomology and cellular four five months seroconversion based on unique severe acute respiratory syndrome 2 (SARS-CoV-2)-specific peptide pool that contains no overlapping peptides...
Gabal El-Missikat post-tectonic granites represent one of the most promising examples fracture-filling uranium occurrences in central Eastern Desert Egypt. It includes several radioactive anomalies which some are associated with U-minerals. These controlled mainly by ENE-WSW trending shear fractures. In present work, a new occurrence (M-III) has been discovered north-western border G. El-Misskat granitic mass. is jasperoid materials, occupying NW-SE reactivated zone tensile properties. The...
First infusion reactions along with severe anaphylactic responses can occur as a result of systemic administration therapeutic antibodies. The underlying mechanisms by which monoclonal antibodies induce cytokine release syndrome (CRS) involve direct agonistic effects via the drug target, or combination target-engagement innate receptor interactions. Despite wide variety pathways and cells that play role in CRS, many currently used assays are devoid one more components must be present for...
Rituximab is widely used in the treatment of haematological malignancies, including chronic lymphocytic leukaemia (CLL), most common adults. However, some patients, especially those with high tumour burden, develop cytokine release syndrome (CRS). It likely that more patients will therapy-linked CRS future due to implementation other immunotherapies, such as CAR T-cell, for many malignancies. Current methods risk assessment are limited, hence there a need new methods. To better recapitulate...
Abstract The agonistic potentials of therapeutic anti‐CD40 antibodies have been profiled in relation to antibody isotype and epitope specificity. Still, clinical impact relies on a well‐balanced efficacy versus target‐mediated toxicity. As CD40‐mediated immune activation must rely combination stimulation antigen‐presenting cells (APCs) alongside antigen presentation, for efficient T cell priming, alternative approaches improve the outcome CD40‐targeting strategies should focus providing...
<h3>Background</h3> Rituximab is widely used in the treatment of haematological malignancies, including chronic lymphoid leukaemia (CLL), most common adults. However, some patients, especially those with high tumour burden, develop cytokine release syndrome (CRS). It likely that more patients will therapy-linked CRS future due to implementation other immunotherapies, such as CAR T-cell, for many malignancies. Current methods risk assessment are limited, hence there a need new methods....
<h3>Background</h3> To induce a prominent anti-tumor T-cell response, viral or tumor derived antigen epitope imbedded in longer synthetic peptide (SLP) can be used, which also requires internalization and processing by presenting cells (APCs) to enable T cell priming. Herein we present the design evaluation of CD40 targeting tetravalent bispecific antibody, binding peptides through affinity as an antibody-drug conjugate. APC activation well vitro vivo proliferation studies demonstrate...
Abstract CD40 agonistic antibodies targeting antigen-presenting cells rely on simultaneous antigen presentation for optimal efficacy, as the co-stimulatory signal alone will not lead to T cell activation. Herein we have developed a novel Adaptable Drug Affinity Conjugate (ADAC), refinement of traditional Antibody (ADC) with focus tailored drug design. The cargo ADAC is synthetic long peptides that can be modified profiled genetic data each patient. technology relies high-affinity interaction...
Human monocyte-derived dendritic cells (moDCs) isolated from blood are cultured with the Adaptable Drug Affinity Conjugate (ADAC), i.e., a bispecific CD40-targeting agonistic antibody. The picture represents activated microscope of ADAC-activated moDCs that cluster together in their state. This is reported by Sara M. Mangsbo and co-workers article number 2200008. photo was taken author Ida Lauren.